TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8500515
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg bumethanide at 0800, 1200, 1800, 2200 (treatment 2)
Study: 8500515
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bendroflumethiazide at 0800 and 1800 (treatment 3)
Study: 27584567
Drug: Intravenous β-blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous β-blockers
Study: 1595785
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg daily) plus low-dose aspirin
Study: 3883732
Drug: oral molsidomine
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral molsidomine (Corvaton, 6 mg/day)
Study: 29490959
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every 3 weeks (taper arm)
Study: 27041257
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and acetaminophen (n = 38)
Study: 22520863
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) for AECOPD administered twice daily over 7 to 21 days, followed by TCM for AECOPD-RW over 28 days.
Study: 10452633
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg daily)
Study: 2198918
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of oral mifepristone
Study: 30709391
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus activation therapy (AT)
Study: 28911934
Drug: Dienogest (DNG)
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest (DNG) 2 mg/d, orally for 16 weeks
Study: 25529904
Drug: Infliximab (TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (TNF antagonist)
Study: 17424753
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (1.5 x ED95)
Study: 10807113
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg bid for 9 months
Study: 25315126
Drug: Ropivacaine 1.5
Normalized name: fentanyl-ropivacaine 1.5 mcg/mL-0.2%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1.5 mg·ml(‐1), 1 ml·kg(‐1) mixed with 50 mg of magnesium (Group RM)
Study: 25315126
Drug: Ropivacaine 1.5
Normalized name: fentanyl-ropivacaine 1.5 mcg/mL-0.2%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1.5 mg·ml(‐1), 1 ml·kg(‐1) (Group R)
Study: 22570185
Drug: Standard single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard single-dose methotrexate treatment
Study: 20026785
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (1500 mg/d)
Study: 16602327
Drug: Oral antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihistamine (cetirizine) on demand (group C)
Study: 7569269
Drug: Pravastatin (HMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (HMG CoA reductase inhibitor), dosage and duration not specified
Study: 2404502
Drug: Extended-release felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release felodipine tablets once daily
Study: 30379826
Drug: Evocalcet 2
Normalized name: evocalcet
DrugBank: Evocalcet (DB12388)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Evocalcet 2 mg/day
Study: 12454315
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (e.g., paclitaxel/trastuzumab or capecitabine/docetaxel)
Study: 10361111
Drug: Intermediate serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate serum hyaluronan (HYA) values (10 to 120 micrograms/L)
Study: 10361111
Drug: Abnormally low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abnormally low HYA values (0 to 9 micrograms/L)
Study: 10361111
Drug: High HYA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High HYA values (>120 micrograms/L)
Study: 2405628
Drug: Low-dose warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose warfarin (average daily dose of 4.6 mg)
Study: 19226611
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy and hypnosis (CBTH)
Study: 18004255
Drug: TIKLO (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIKLO (250 mg, BID)
Study: 18004255
Drug: Thrombo ASS
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombo ASS (100 mg, QD)
Study: 7914611
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day amiodarone
Study: 23510493
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg for 6 weeks, then increased to 10 mg till week 12, then hydrochlorothiazide 25 mg added
Study: 23510493
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg till week 6, then amlodipine 5‐10 mg added
Study: 11690571
Drug: Plasma fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma fibrinogen levels (baseline <314 mg/dL)
Study: 11690571
Drug: Plasma fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma fibrinogen levels (314 to 373 mg/dL)
Study: 11690571
Drug: Plasma fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma fibrinogen levels (>373 mg/dL)
Study: 11690571
Drug: Upper tertile
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper tertile of fibrinogen levels (>373 mg/dL)
Study: 7875187
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate extended-release (ISDN-ER) 10 mg immediate release and 60 mg slow release
Study: 7875187
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate extended-release (ISDN-ER)
Study: 8477320
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment only for reflux grade III or less
Study: 1868479
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus antibiotic treatment for reflux grade IV
Study: 8477320
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment alone for reflux grade IV
Study: 23676933
Drug: Oxcarbazepine (OXC)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXC) suspension
Study: 17711537
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) tablets
Study: 20233196
Drug: S-0139 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-0139 (15 μg kg-1 min-1)
Study: 20233196
Drug: S-0139 (15.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-0139 (15.7 μg kg-1 min-1) in delayed administration study
Study: 20233196
Drug: S-0139 (0.08-13.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-0139 (0.08-13.33 μg kg-1 min-1) in pilot study
Study: 16496208
Drug: Double IUI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double IUI (two inseminations 18-24 and 36-48 hours post hCG injection)
Study: 16496208
Drug: Single IUI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IUI (one insemination 34 hours post hCG administration)
Study: 11224838
Drug: Individualized homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homeopathic medicine
Study: 1695783
Drug: Nonsurgical or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical or surgical treatment for BPH
Study: 324177
Drug: Live dysentery
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live dysentery Sonne vaccine (3 to 25 milliard live microbial cells, single and triple immunization schemes)
Study: 324177
Drug: Live dysentery
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live dysentery Sonne vaccine
Study: 12188171
Drug: Topical glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glaucoma medications
Study: 25557395
Drug: Emotion Regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion Regulation Group Therapy (ERGT)
Study: 7926139
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg locally
Study: 3617193
Drug: Combined supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplement of iron, thiamine, riboflavin, and vitamin C for 3 months
Study: 28842994
Drug: Preservative- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative- and adjuvant-free trivalent split vaccine
Study: 1859751
Drug: Neostigmine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.05 mg kg‐1
Study: 22638811
Drug: d-amphetamine 40
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 40 mg
Study: 22638811
Drug: d-amphetamine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (both doses)
Study: 12459402
Drug: Lead chelation
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead chelation therapy
Study: 7954994
Drug: Midazolam loading
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam loading dose of 0.03 mg.kg-1 and infusion rate of 0.5 micrograms.kg-1.min-1
Study: 26724628
Drug: Combined EVD
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined EVD and Ommaya reservoir with urokinase (20,000 IU/dose)
Study: 19294387
Drug: CI-1033 50
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-1033 50 mg daily (arm A)
Study: 15563362
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoconazole administered orally every 24 h for 29 days
Study: 12035596
Drug: Brinzolamide in
Normalized name: Product containing brinzolamide in ocular dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide in combination with other therapies
Study: 3310629
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g three times a day one‐half hour before meals for four weeks)
Study: 25016780
Drug: IL-6 serum
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 serum level in patients with colon adenomas (19.80 +/- 7.44 pg/ml)
Study: 7559897
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analog (Buserelin) in combination with cyproterone acetate (Androcur); n = 23
Study: 17353513
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg) + HCTZ (25 mg)
Study: 17353513
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg) + HCTZ (25 mg)
Study: 7755647
Drug: Gemfibrozil treatment
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil treatment
Study: 8582390
Drug: Beta-blocker (acebutalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (acebutalol or atenolol)
Study: 219509
Drug: timolol-hydrochlorothiazide-amiloride combination
Normalized name: amiloride / hydrochlorothiazide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol-hydrochlorothiazide-amiloride combination
Study: 219509
Drug: beta-blocker (timolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker (timolol) alone
Study: 219509
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of two diuretics (hydrochlorothiazide + amiloride)
Study: 1979634
Drug: beta-blocker/diuretic combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker/diuretic combination
Study: 12960909
Drug: Dalteparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (5000 IU subcutaneously once daily)
Study: 12960909
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg subcutaneously every 12 hr)
Study: 2061445
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% cyclosporine in oily solution
Study: 2061445
Drug: Intravenous thymopentin
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thymopentin
Study: 6352005
Drug: prednimustine intermittently;
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednimustine intermittently; 160 mg/m2 d 1 to 5, repeated every three weeks
Study: 6352005
Drug: chlorambucil 8
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chlorambucil 8 mg/m2 d plus prednisolone 8 mg/m2 d, both given continuously
Study: 30851006
Drug: Self-managed titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-managed titration of Gla-300
Study: 26601770
Drug: Autonomic regulation
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic regulation therapy (ART) with chronic vagus nerve stimulation
Study: 17506903
Drug: Supervised, weekly,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised, weekly, hospital-based exercise
Study: 1716558
Drug: Scopolamine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (3 doses)
Study: 29560570
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tablets
Study: 24876619
Drug: Oral hepatic-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hepatic-directed vesicle-insulin (HDV-I) 0.05 U/kg
Study: 24876619
Drug: Oral hepatic-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hepatic-directed vesicle-insulin (HDV-I) 0.1 U/kg
Study: 24876619
Drug: Oral hepatic-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hepatic-directed vesicle-insulin (HDV-I) 0.2 U/kg
Study: 24876619
Drug: Oral hepatic-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hepatic-directed vesicle-insulin (HDV-I) 0.4 U/kg
Study: 10547079
Drug: Losartan, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan, 75 mg/day
Study: 9857880
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal GTN, 0.6 mg/h
Study: 1855357
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day enalapril
Study: 1855357
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day enalapril
Study: 6185553
Drug: Cromolyn 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn 2% (nonirritant dose)
Study: 31602822
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate in capsules (500 mg·kg‐1 body mass)
Study: 26748056
Drug: Implant removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant removal surgeries
Study: 24281290
Drug: Epidural racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural racemic ketamine 0.5 mg/kg preincisional +0.25 mg/kg/h for 48 h
Study: 3996172
Drug: Social skills
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social skills intervention group (daily social-learning exercises)
Study: 15825529
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride ophthalmic solution, one instillation four times daily for 21 days
Study: 10506606
Drug: DepoCyt 50
Normalized name: DepoCyt 50 MG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoCyt 50 mg once every 2 weeks
Study: 10506606
Drug: Free ara-C
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Free ara-C 50 mg twice a week for 1 month
Study: 8894655
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Heparin)
Study: 2852903
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2 mg
Study: 30070742
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil capsules (menthol)
Study: 27196485
Drug: Nefopam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (20 mg administered before surgery)
Study: 23583433
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg eluxadoline
Study: 23583433
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg eluxadoline
Study: 23583433
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg eluxadoline
Study: 21916043
Drug: Ultragrivac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultragrivac vaccine with 21 day interval
Study: 11298665
Drug: Almotriptan 12.5
Normalized name: almotriptan 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 12.5 mg on day 7 with propranolol 80 mg twice daily for 7 days
Study: 10674661
Drug: Whole cell/recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell/recombinant B subunit cholera vaccine
Study: 8697924
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (ASA, 50mg/day) for more than two weeks
Study: 786671
Drug: Indoprofen (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoprofen (up to 400 mg)
Study: 28445790
Drug: Nurse-led group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led group treatment for insomnia based on cognitive behavioral therapy techniques; 2 days of training for nurses.
Study: 23720354
Drug: Multi-agent chemotherapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-agent chemotherapy including high dose methotrexate, Ara-C, and intrathecal treatment
Study: 18385263
Drug: Methylergometrine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylergometrine (0.2 mg i.v.)
Study: 23839254
Drug: Chorionic membrane
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chorionic membrane (CM) with periodontal pocket therapy
Study: 23839254
Drug: Periodontal pocket
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periodontal pocket therapy alone (Control)
Study: 22300693
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 500 mg twice daily for 4 weeks
Study: 19088307
Drug: Control formula
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formula supplemented with PDX, GOS, and lactulose (4 g/liter) (PGL4 group; n = 27)
Study: 19088307
Drug: Control formula
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formula supplemented with PDX, GOS, and lactulose (8 g/liter) (PGL8 group; n = 25)
Study: 17169532
Drug: Single low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single low-level systemic hyperthermia treatment in scleroderma patients (n=46)
Study: 7639162
Drug: RV‐>patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV‐>patch
Study: 7639162
Drug: RV‐>patch +
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV‐>patch + SVC
Study: 7027430
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of salsalate
Study: 30621717
Drug: Indacaterol/glycopyrronium 110/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium 110/50 μg once daily (IND/GLY)
Study: 30621717
Drug: Salmeterol/fluticasone 50/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone 50/500 twice daily (SFC)
Study: 27861991
Drug: Evolocumab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (various doses from 7-420 mg SC)
Study: 25651476
Drug: Ibogaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibogaine (20 mg) with paroxetine pretreatment
Study: 24335445
Drug: AZD9773 low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZD9773 low dose (250 U/kg followed by 50 U/kg every 12 hours)
Study: 24335445
Drug: AZD9773 high
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9773 high dose (500 U/kg followed by 100 U/kg every 12 hours)
Study: 22659487
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 μg od)
Study: 11955393
Drug: Single 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 80 mg epirubicin
Study: 11955393
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg consecutive epirubicin